Department of Pharmacology and Experimental Therapeutics

Kenneth Bachmann

Kenneth Bachmann
Emeritus Professor of Pharmacology
Former Co-Director, Center for Applied Pharmacology



B.S.     The Ohio State University
Ph.D.     The Ohio State University

Research Interests

  • Drug Metabolism and Disposition
  • Predicting and Characterizing Drug-Drug Interactions in Humans In Vivo
  • Predicting Drug Disposition and Drug-Drug Interactions in Humans from Pre-Clinical and In Vitro Data

Selected Publications

  • BACHMANN, K., SHAPIRO, R., and MACKIEWICZ, J.: Influence of renal dysfunction on warfarin plasma protein binding. J. Clin. Pharmacol. 16:468-472, 1976.

  • BACHMANN, K., SHAPIRO, R., and MACKIEWICZ, J.: Warfarin disposition and responsiveness in patients with renal dysfunction. J. Clin.Pharmacol. 17:292-300, 1977.

  • BACHMANN, K., SHAPIRO, R., FULTON, R., CARROLL, F. and SULLIVAN, T.: Smoking and warfarin disposition. Clin. Pharmacol.Ther. 25:309-315, 1979.

  • BACHMANN, K., VALENTOVIC, M., and SHAPIRO, R.,: A potential role for cyanate in the albumin binding defect in uremia. Biochemical Pharmacology 29:1598-1601, 1980.

  • BACHMANN, K., VALENTOVIC, M. and SHAPIRO, R.: The contribution of cyanate to the albumin binding defect of uremia. Biochemical Pharmacology 30:1059-1063, 1981.

  • BACHMANN, K., SCHWARTZ, J., FORNEY, Jr., R., and JAUREGUI, L.: Theophylline kinetics: dose dependency and single sample prediction of clearance. Pharmacology 30:126-144, 1985.

  • BACHMANN, K., SCHWARTZ, J., FORNEY, Jr., R., and JAUREGUI, L.: Phenytoin as a probe of drug metabolism: predicting clearance with a salivary sample. Pharmacology 30:145-152, 1985.

  • BACHMANN, K., SCHWARTZ, J., FORNEY, Jr., R. and JAUREGUI, L.: Inability of ibuprofen to alter single dose phenytoin disposition. Br. J. Clin.Pharmacol. 21:165-169, 1986.

  • SCHWARTZ, J., JAUREGUI, L., LETTIERI, J., and BACHMANN, K.: Impact of ciprofloxacin on theophylline clearance and steady state serum concentrations. Antimicrobial Agents and Chemotherapy 32:75-77, 1988.

  • BACHMANN, K., SCHWARTZ, J., and JAUREGUI, L.: Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements. Br. J. Clin. Pharmacol. 26:191-194, 1988.

  • JAUREGUI, L., SCHWARTZ, J., REITBERG, D., and BACHMANN, K.: Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients. Antimicrobial Agents Chemother. 32:730-735, 1988.

  • BACHMANN, K., NUNLEE, M., MARTIN, M., and JAUREGUI, L.,: The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of phenobarbitone on human drug metabolism. Xenobiotica 21:1385-1392, 1991.

  • BACHMANN, K., SULLIVAN, T.J., MAURO, L., MARTIN, M., JAUREGUI, L., AND LEVINE, L.: Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients. J. Clin Pharmacol. 32:476-482, 1992.

  • BACHMANN, K., JAUREGUI, J., SIDES, G., AND SULLIVAN, T.: Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin . J. Clin. Pharmacol. 33:861-865, 1993.

  • BACHMANN, K., SULLIVAN, T., AND JAUREGUI, L.: A controlled comparison of continuous ranitidine and intermittent famotidine infusions on gastric pH. J. Clin. Pharmacol. 33:1219-1224, 1993.

  • SULLIVAN, T.J. REESE, J.H., JAUREGUI, L., MILLER, K., LEVINE, L., AND BACHMANN, K.: A comparative study of the interaction between antacid and H-2 receptor antagonists. Alimentary Pharmacol and Therapeutics 8:123-126, 1994.

  • BACHMANN, K., SULLIVAN, T.J., REESE, J.H., JAUREGUI, L., MILLER, K., SCOTT, M., YEH, K.C., STEPANAVAGE, M., KING, J., AND SCHWARTZ, J.: Controlled study of the putative interaction between famotidine and theophylline in COPD patients. J. Clin Pharmacol. 35:529-535, 1995.

  • BACHMANN, K., SULLIVAN, TIMOTHY J., REESE, JAMES H., JAUREGUI, LUIS, MILLER, KRISTEN, SCOTT, MARY, SIDES, GREGORY D., SHAPIRO, RONALD: The influence of dirithromycin on the pharmacokinetics of cyclosporine in healthy subjects and in renal transplant patients. Am. J. Ther. 2:490-498, 1995.

  • BACHMANN, K., PARDOE, D., AND WHITE, D: Scaling basic toxicokinetic parameters from rat to man. Environ. Health Perspectives 104:400-407, 1996.

  • SARVER, J G, WHITE D, ERHARDT P, AND BACHMANN, K.: Estimating xenobiotic half-lives in humans from rat data:Influence of log P. Env. Health Perspectives 105:1204-1209, 1997.

  • SLAMA, J., HANCOCK, J., RHO, T., BACHMANN, K.: Influence of N-substituted azoles and pyridines on rat hepatic CYP3A activity: Biochemical Pharmacology 55:1881-1892, 1998.

  • LIU D, and BACHMANN, K.: An investigation of the relationship between estrogen, estrogen metabolites, and blood cholesterol levels in ovariectomized rats. J. Pharmacol Exp. Ther. 286:561-568, 1998.

  • BACHMANN, K. and Ghosh R: The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Current Drug Metabolism 2:299-314, 2001.

  • SCHWARTZ J., AGRAWAL N., WONG P., BACHMANN, K., PORRAS A., MILLER J., EBEL D., SACK M., HOLMES G., REFERN J. AND GERTZ B.: Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients J. Clin Pharmacol. 41:1120-1130,2001

  • HUANG B., BACHMANN, K., HE X., CHEN R., McALLISTER JS, and WONG T.:Inappropriate prescriptions for the aging population of the United States:An analysis of the National Ambulatory MedicalCare Survey, 1997. Pharmacepidemiology and Drug Safety 11:127-134,2002.

  • BACHMANN, K., Ring B., and Wrighton SA:Drug-drug interactions and the cytochromes P450 in Cytochrome P450 and Drug Metabolism, Frederick Fenter and Jae S. Lee eds., FontisMedia, Lausanne, Switzerland, pp 375-400, 2003.

  • SCHATZ R, BELLOTO Jr, RJ, and BACHMANN, K: Provision of drug information to patients by pharmacists:The impact of OBRA �90 a decade later. American Journal of Therapeutics 10: 93-103, 2003.

  • BACHMANN, K., HE Y, SARVER JG, AND PENG N.: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica 33:265-276, 2003.

  • BACHMANN, K., Jauregui J, Chandra R, and THAKKER K: Influence of a three-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. Pharmacological Research 47:549-554, 2003.

  • BACHMANN, K., BYERS J, AND GHOSH R.:Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica 33:475-483, 2003.

  • BACHMANN, K., (Sr. Ed) LEWIS J, FULLER M, AND BONFIGLIO M (Eds): Drug Interactions Handbook, 2nd Ed Lexicomp, Inc., Hudson Ohio, 2004

  • BACHMANN, K., WHITE D, JAUREGUI L, SCHWARTZ J, AGRAWAL N, MAZENKO R, and PORRAS A: Dose-dependent interaction between rofecoxib and theophylline. J. Clin. Pharmacol. 43:1082-1090, 2003.

  • BACHMANN, K:Quantitative issues pertaining to drug metabolism and drug-drug interactions. Current Drug Metabolism 4:i-iv, 2003.

  • NIRO R, FOURNIER R, BACHMANN, K., and BYERS J:In vitro to in vivo prediction of drug metabolism using cryopreserved hepatocytes and a convective dispersion model. Current Drug Metabolism 4:357-369, 2003.

  • BACHMANN, K., PATEL H, BATAYNEH Z, SLAMA J, WHITE D, POSEY J, EKINS S, GOLD D, AND SAMBUCETTI L:PXR and the regulation of ApoA1 and HDL-cholesterol in rodents. Pharmacol. Res. 50 :237-246,2004).

  • BACHMANN, K., TELANG U, AND HOSS W:The processing of the selective M1 agonist, CDD-0102-J, by human hepatic drug metabolizing enzymes. Pharmacol. Res. (in press, Am J. Therapeutics)

  • HUANG B., MARTIN S, BACHMANN, K., HE X, REESE J, WONG T, AND CHEN R.: Antibiotic prescriptions for respiratory tract infections during physician office visits in the United States:an analysis of the National Ambulatory Medical Care Survey, 1999. (in press Journal of Clinical Epidemiology)

  • WHITE D, BACHMANN, K. AND BATAYNEH Z: A Response Surface Model for Synergism between the PPARa agonist, gemfibrozil, and the PXR agonist, CDD 3540 3540, in modifying serum HDL cholesterol and apoA1. (in preparation)

  • BACHMANN, K. AND LEWIS J.; Enzyme Inhibitory Constants and Concentration Values in Evaluating and Predicting Drug Interactions. (submitted, Annals of Pharmacotherapy)

  • WARD K, ERHARDT P, AND BACHMANN, K.: Comparative application of simple mathematical expressions to relate rat and human xenobiotic half-life (in press, J Pharmacol Toxicol Methods)
Last Updated: 6/9/16